Regeneron Pharmaceuticals announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorization Application, MAA, for odronextamab to treat adult patients with relapsed/refractory follicular lymphoma, FL, or R/R diffuse large B-cell lymphoma, who have progressed after at least two prior systemic therapies. The EMA previously granted odronextamab Orphan Drug Designation for FL and DLBCL. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. The MAA is supported by data from a Phase 1 and pivotal Phase 2 trial investigating odronextamab in FL and DLBCL, which were last presented at the 64th American Society of Hematology Annual Meeting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Regeneron announces PULSAR trial met its primary endpoint
- Decibel Therapeutics (NASDAQ:DBTX) Skyrockets On Acquisition By Regeneron
- Decibel Therapeutics downgraded to Neutral from Buy at H.C. Wainwright